EP0695175A1 - Compositions pharmaceutiques enrobees - Google Patents

Compositions pharmaceutiques enrobees

Info

Publication number
EP0695175A1
EP0695175A1 EP94914159A EP94914159A EP0695175A1 EP 0695175 A1 EP0695175 A1 EP 0695175A1 EP 94914159 A EP94914159 A EP 94914159A EP 94914159 A EP94914159 A EP 94914159A EP 0695175 A1 EP0695175 A1 EP 0695175A1
Authority
EP
European Patent Office
Prior art keywords
composition
pharmaceutical
cold
pharmaceutical composition
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
EP94914159A
Other languages
German (de)
English (en)
Inventor
Carmelita Macklin Russel
Allen I. Dines
James Grigg Upson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Procter and Gamble Co
Original Assignee
Procter and Gamble Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Procter and Gamble Co filed Critical Procter and Gamble Co
Publication of EP0695175A1 publication Critical patent/EP0695175A1/fr
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/282—Organic compounds, e.g. fats

Definitions

  • the present invention relates to pharmaceutical compositions for oral administration coated with one or more volatile aromatics select ⁇ ed from the group consisting of 3-1-menthoxy propane-l,2-diol, N- substituted-p-menthane-3-carboxamides and acyclic carboxamides and mixtures thereof.
  • the common cold although not usually a serious illness, is a highly prevalent, discomforting and annoying infliction.
  • the term "common cold” is applied to minor respiratory illnesses caused by a variety of different respiratory viruses. While rhinoviruses are the major known cause of common colds, accounting for approximately 30 percent of colds in adults, viruses in several other groups are also important. While immune responses occur, and infection with some respiratory tract viruses therefore could be prevented by a vaccine, development of a polytypic vaccine to cover all possible agents is impractical. Thus, the problem of controlling acute upper respiratory disease presents complex challenges, and the long-desired discovery of a single cure for the common cold is an unrealistic expectation.
  • Typical symptoms of the common cold are mild malaise, sore throat and nasal complaints. Nasal discharge, nasal congestion and/or sneezing frequently are present. Also common are sore, dry or scra ⁇ tchy throat and hoarseness and cough. Other symptoms may include mild burning of the eyes, loss of smell and taste, a feeling of pressure or fullness in the sinuses or ears, headache, and vocal impairment. Flu symptoms are similar but usually of greater severity, including fever, generalized aches and pains, fatigue and weakness, and chest discom ⁇ fort. Allergy symptoms are more akin to the common cold, with more frequent/severe sinus pressure, drainage and headaches.
  • compositions safe and effective for treating colds, flu, and allergies are well known. Over-the-counter medica ⁇ tions provide symptomatic relief of such illnesses. At present, only symptomatic treatment is available for the common cold; the majority of these drugs are taken orally.
  • Exemplary prior art oral composi ⁇ tions for treatment of nasal and other cold, flu, allergy and sinus symptoms and the discomfort, pain, fever and general malaise associ ⁇ ated therewith generally contain an analgesic (aspirin or acetamino ⁇ phen) and one or more antihistamines, decongestants, cough suppres ⁇ sants, antitussives and expectorants.
  • nasal symptoms e.g., congestion
  • Other specific pharmaceutical actives for nasal symptoms generally contain either 5 oxymetazoline or phenylephrine. These actives are generally delivered topically to the nasal mucosa via a nasal spray.
  • oral drugs such as decongestants could pose a risk of unfavorable drug interactions and may cause an adverse
  • Coated pharmaceutical compositions have also been used to provide improved aesthetics, taste- and/or odor-masking and to provide flavor ⁇ ing and fragrances to tablets and the like, see, for example, U.S. Patent 5,089,715 to McCabe et al., issued March 24, 1992.
  • oral pharmaceutical compositions coated with one or more of a volatile aromatic compound selected from the group consisting of 3-1-menthoxy propane-l,2-diol, N-substituted- p-menthane-3-carboxamides and acyclic carboxamides thereof provide the user with improved actual and/or perceived relief from nasal symptoms
  • compositions will not cause drowsiness or other side effects attendant with oral decongestants.
  • It general malaise associated therewith typically contain one or more of the pharmaceutical actives which are analgesics, anesthetics, antihis- tamines, decongestants, cough suppressants, antitussives and expectora
  • Another object is to provide such compositions and methods having improved actual and/or perceived benefits, e.g., speed of relief and/or duration of relief, and/or improved aesthetics.
  • the present invention is directed to pharmaceutical compositions suitable for coating comprising a composition for oral administration in unit dosage form wherein said composition has been coated with from about 0.01% to about 10% by weight of the composition with a volatile aromatic compound selected from the group consisting of 3-1-menthoxy propane-l,2-diol, N-substituted-p-menthane-3-carboxamides and acyclic carboxamides and mixtures thereof.
  • a volatile aromatic compound selected from the group consisting of 3-1-menthoxy propane-l,2-diol, N-substituted-p-menthane-3-carboxamides and acyclic carboxamides and mixtures thereof.
  • the present invention is also directed to methods for treating cough, cold, cold-like, allergy, and flu symptoms in a human or lower animal, said method comprising administering these compositions to a human or lower animal in need of such treatment.
  • the present invention relates to pharmaceutical compositions suitable for coating comprising a composition for oral administration in unit dosage form wherein said composition has been coated with from about 0.01% to about 10% by weight of the composition with a volatile aroma ⁇ tic compound selected from the group consisting of 3-1-menthoxy propane-l,2-diol, N-substituted-p-menthane-3-carboxamides and acyclic carboxamides and mixtures thereof.
  • a volatile aroma ⁇ tic compound selected from the group consisting of 3-1-menthoxy propane-l,2-diol, N-substituted-p-menthane-3-carboxamides and acyclic carboxamides and mixtures thereof.
  • compositions of the present invention are coated with a coating comprising a volatile aromatic selected from the group consisting of 3-1-menthoxy propane-l,2-diol, N-substituted-p- menthane-3-carboxamides and acyclic carboxamides and mixtures thereof. While not to be limited by theory, it is believed that the benefits obtained by the use of these coolants in the compositions of the present invention are the result of the unique cooling profiles for these compounds.
  • N-substituted-p-menthane-3-carboxamides are fully described in U.S. Patent 4,135,163 to Watson et al., issued January 23, 1979 incorporated herein by reference in its entirety.
  • the most preferred volatile aromatic of this class is N-ethyl-p-menthane-3-carboxamide which is commercially available as WS-3 from Wilkinson Sword Limited.
  • Preferred for use herein is a mixture of 3-1-menthoxy propane 1,2-diol and N-ethyl-p-menthane-3-carboxamide in a ratio of about 3:1.
  • the most preferred coating comprises a mixture of 3-1-menthoxy propane 1,2-diol, N-ethyl-p-menthane-3-carboxamide and N,2,3-trimethyl-2- isopropylbutana ide in a ratio of 2:1:1, respectively.
  • volatile aromatic compounds are present at a level of from about 0.001% to about 10%, preferably at from about 0.001% to about 5%, more preferably from about 0.001% to about 0.5% by weight of the pharmaceutical compositions of the present invention.
  • volatile aromatic materials can be applied directly to the compositions of the present invention, or incorporated into a pharmaceutically-acceptable coating as described below.
  • oral dosage forms suitable for coating can be used, including such solid forms as tablets, capsules, pills and lozenges. These oral forms can contain a safe and effective amount of a pharma ⁇ ceutical active component.
  • Solid oral dosage forms preferably com ⁇ prise from about 0.1% to about 99%, more preferably from about 25% to about 99%, and most preferably from about 50% to about 99% of a pharmaceutical active component.
  • These dosage forms contain compatible solid or liquid filler diluents or encapsulating substances which are suitable for oral administration to a human or lower animal.
  • compatible means that the components of the compositions of the present invention are capable of being commingled with the pharmaceu ⁇ tical active, and with each other, in a manner such that there is no interaction which would substantially reduce the pharmaceutical efficacy of the compositions under ordinary use situations.
  • Pharma- ceutically-acceptable carrier materials must, of course, be of suffi ⁇ ciently high purity and sufficiently low toxicity to render them suitable for administration to the human being treated.
  • the present invention compositions comprise from about 0.1% to about 99.99% of one or more pharmaceutically-acceptable carrier materials.
  • Tablets can be compressed, molded, triturated, enteric-coated, sugar-coated, film-coated or multiple compressed, containing suitable binders, lubricants, diluents, disintegrating agents, coloring agents, flavoring agents, preservatives and flow-inducing agents.
  • soft and hard gelatin capsules wherein the shell is either coated, or alternatively, the volatile aromatic compound is contained within the shell material.
  • the gelatin shell i essentially transparent so as to enhance the aesthetic qualities o the capsule.
  • Soft and hard gelatin shells generally comprise gelatin, a plasticizer and water.
  • the starting gelatin material generally use in the manufacture of these capsules is obtained by the partial hydrolysis of collagenous material.
  • Gelatin suitable for capsul manufacture is commercially available from the Sigma Chemical Company, St. Louis, Mo. For a general description of gelatin and gelatin-based capsules, see Remington's Pharmaceutical Sciences. 16th ed., Mack
  • plasticizers is incorporated to produce a gelatin shell.
  • Useful plasticizers of the present invention include glycerin, sorbitan, sorbitol, or similar low molecular weight polyols, and mixtures thereof.
  • the gelatin shells of the instant invention can be prepared by combining appropriate amounts of gelatin, water, plasticizer, and any optional components in a suitable vessel and agitating and/or stirring while heating to about 65°C until a uniform solution is obtained.
  • Hard gel capsules can then be used for encapuslating the desired quantity of fill material employing methods known to the skilled artisan.
  • Soft gelatin shell compositions containing the desired quantity of the fill composition are made by employing standard encapsulation methodology to produce one-piece, hermetically sealed, soft gelatin capsules.
  • the gelatin capsules are formed into the desired shape and size so that they can be readily swallowed.
  • the gelatin capsules of the instant invention are of a suitable size for easy swallowing and typically contain from about 100 mg to about 2000 mg of the pharmaceu ⁇ tical active composition.
  • the coolant can be added either as a seperate coating applied directly to the gelatin capsule, or it can be incorporated into the gelatin capsule shell itself without the need for a seperate coating step.
  • Gelatin capsules and encapsulation methods are described in P.K. Wilkinson et al., "Softgels: Manufactur ⁇ ing Considerations", Drugs and the Pharmaceutical Sciences. 41 (Spe ⁇ cialized Drug Delivery Systems). P. Tyle, Ed.
  • ingredients well known to the pharmacist's art may also be included in amounts generally known for these ingredients, for example, natural or artificial sweeteners, flavoring agents, colorants and the like to provide a palatable and pleasant looking final prod ⁇ uct, antioxidants, for example, butylated hydroxy anisole or butylated hydroxy toluene, and preservatives, for example, methyl or propyl paraben, potassium sorbate, or sodium benzoate, to prolong and enhance shelf life.
  • antioxidants for example, butylated hydroxy anisole or butylated hydroxy toluene
  • preservatives for example, methyl or propyl paraben, potassium sorbate, or sodium benzoate, to prolong and enhance shelf life.
  • a preferred optional component is also caffeine.
  • compositions according to the present inven ⁇ tion optionally comprise a safe and effective amount of a pharmaceuti ⁇ cal active, preferably a pharmaceutical colds actives useful for treating cough, cold, cold-like, allergy and/or flu symptoms.
  • a pharmaceutical colds actives useful for treating cough, cold, cold-like, allergy and/or flu symptoms.
  • Such pharmaceutical actives are well known, and are generally recognized as being an active having analgesic, anti-inflammatory, anesthetic, antihistamine, decongestant, cough suppressant, demulcents, antitus- sive, and/or expectorant properties.
  • safe and effective amount means an amount of a compound or composition high enough when administered orally to significantly positively modify the condition to be treated, but low enough to avoid serious side effects (at a reasonable bene ⁇ fit/risk ratio), within the scope of sound medical judgment.
  • the safe and effective amount of the pharmaceutical active will vary with the particular condition being treated, the age and physical condition of the patient being treated, the severity of the condition, the duration of the treatment, the nature of concurrent therapy, the specific pharmaceutical active employed, the particular pharmaceutically- acceptable carrier utilized, and like factors within the knowledge and expertise of the attending physician.
  • the pharmaceutical active(s) comprise from about 0.001% to about 99.9%, by weight, of the pharmaceutical compositions of the present invention, preferably from about 0.001% to about 75%, and most preferably from about 0.01% to about 30%.
  • actives commonly utilized in cough/cold preparations are, for example, a decongestant such as pseudoephedrine, phenyl - propanolamine, phenylephrine and ephedrine, their pharmaceutically ac ⁇ ceptable salts; an antitussive such as dextromethorphan, chlophedia- nol , carbetapentane, caramiphen, noscapine, diphenhydramine, codeine, menthol, hydrocodone, hydro orphone, fominoben, their pharmaceutical- ly-acceptable salts; an expectorant or mucolytic such as glyceryl guaiacolate, terpin hydrate, ammonium chloride, N-acetylcysteine and bromhexine, ambroxol, their pharmaceutically acceptable salts; and an antihistamine such as chlorphenira ine, brompheniramine, dexchlorphen- iramine, dexbromphren
  • Patent 4,783,465 to Sunshine et al. issued November 8, 1988
  • U.S. Patent 4,619,934 to Sunshine et al. issued October 28, 1986, which are incorporated by reference herein.
  • bronchodilators such as terbutaline, atropine, amino- phylline, epinephrine, isoprenaline, metaproterenol, bitoterol, theophylline and albuterol.
  • analgesic compounds such as aspirin, acetaminophen, ibuprofen, and naproxen; and topical anesthe ⁇ tics/analgesics such as phenol, benzocaine, hexyl resorcinol, and dyclonine.
  • ingestible pharma ⁇ ceutical agents effective for treating the gastrointestinal tract e.g., symptoms such as heartburn, stomachache and indigestion
  • ingestible pharma ⁇ ceutical agents effective for treating the gastrointestinal tract e.g., symptoms such as heartburn, stomachache and indigestion
  • bismuth-containing agents and H2 receptor-blocking anti-secretory agents e.g., bismuth-containing agents and H2 receptor-blocking anti-secretory agents.
  • Preferred antacid agents have stomach acid neutralizing capacities, such as those agents selected from the group consisting of: aluminum carbonate, aluminum hydroxide, aluminum phosphate, aluminum hydroxy-carbonate, dihydroxy aluminum sodium carbonate, aluminum magnesium glycinate, dihydroxy aluminum amino acetate, dihydroxy aluminum aminoacetic acid, calcium carbonate, calcium phosphate, aluminum magnesium hydrated sulfates, magnesium aluminate, magnesium alumino silicates, magnesium carbonate, magnesium glycinate, magnesium hydroxide, magnesium oxide, magnesium trisilicate, sucralfate, and mixtures thereof.
  • stomach acid neutralizing capacities such as those agents selected from the group consisting of: aluminum carbonate, aluminum hydroxide, aluminum phosphate, aluminum hydroxy-carbonate, dihydroxy aluminum sodium carbonate, aluminum magnesium glycinate, dihydroxy aluminum amino acetate, dihydroxy aluminum aminoacetic acid, calcium carbonate, calcium phosphate, aluminum magnesium hydrated sulfates, magnesium aluminate, magnesium alumino silicate
  • Bismuth-containing agents include, for example, bismuth subsalicylate, bismuth aluminate, bismuth ci ⁇ trate, bismuth subcitrate, bismuth nitrate, bismuth subcarbonate, bismuth subgalate, and mixtures thereof.
  • a particularly preferred bismuth salt is bismuth subsalicylate.
  • H2 receptor-block- ing anti-secretory agents include ranitidine and cimetidine.
  • Pre ⁇ ferred antacid agents for use herein are aluminum hydroxide, magnesium hydroxide, dihydroxy aluminum sodium carbonate, calcium carbonate, and mixtures thereof. Most preferred is calcium carbonate.
  • calcium channel blockers beta-blockers, antibacterials, antidepres- sants, antidiabetics, anti-emetics, cerebral stimulants, sedatives, anti-parasitics, diuretics, muscle relaxants, anti-Parkinsonian agents, bronchodilators, cardiotonics, antibiotics, antivirals, nutritional supplements (such as vitamins, minerals, fatty acids, amino acids, and the like), and mixtures thereof.
  • the volatile aromatic coolants of the present invention are applied directly to the surface of the dosage form alone, or preferably by being incorporated into any conventional pharmaceutically-acceptable coating. Suitable coating techniques are described in Remington's Pharmaceutical Sciences. 17th ed., Mack Publishing Company, Easton, Pa. (1985), pages 1233-43, this reference being incorporated herein by reference.
  • the preferred film coating of this invention is comprised of a commercial film-coating product designed for aqueous film coating containing a water-soluble, film- forming resin, hydroxypropyl methylcellulose and polyethylene glycol (or other suitable plasticizing agents such as propylene glycol or glycerin) and optionally containing titanium dioxide (or other color ⁇ ant or opacifying agent).
  • Such a product is commercially available under the trade name Opadry WhiteTM (Colorcon, West Point, Pa.).
  • a suitable blend comprises 0 to about 20% w/w titanium dioxide or colorant, about 5 to about 95% w/w hydroxypropyl methylcellulose, and 0 to about 25% w/w polyethylene glycol.
  • the most preferred embodiment comprises 10.5% non-water additives, of which 7.5% is Opadry. There ⁇ fore, most of the weight of the non-water additives of the coating dispersion is comprised of Opadry. More than 25% Opadry makes the coating too thick to spray easily while concentrations that are too low decrease the efficiency of coating.
  • This blend plus flavoring and sweetening agents is added to purified water at ambient temperature in a vortex mixer such as a Lightnin Mixer Model V-7 (Mixing Equipment Co., Rochester, N.Y.).
  • a vortex mixer such as a Lightnin Mixer Model V-7 (Mixing Equipment Co., Rochester, N.Y.).
  • Other Opadry coating products such as Opadry Clear or Opadry with various pigment lakes may also be used in the invention to change the appearance of the tablets without adversely affecting the flavor characteristics of the invention.
  • Other aqueous film-forming polymers may also be employed in place of hydroxypropyl methylcellulose.
  • the present invention also relates to a method for treating cough, cold, cold-like, allergy and flu symptoms in a human or lower animal. Said method comprises administering to a human or lower animal in need of such treatment the compositions of the present invention.
  • a coated tabl et composition for oral admini stration i s prepared by combi ning the fol l owing ingredients : Tabl et :
  • the acetaminophen, povidone and lactose are blended together.
  • the alcohol is added slowly and mixed well.
  • the wet mass is screened through a #4 mesh screen.
  • the granulation is dried at 50*C overnight and then sized through a #20 mesh screen.
  • the remaining ingredients are bolted through a #60 mesh screen.
  • the two granulations are mixed and then compressed into tablets using conventional tableting equip ⁇ ment known to those skilled in the art.
  • the tablets are then pan coated with the coating mixture using conventional coating equipment.
  • Administration of 1 or 2 of the above tablets to a human in need of treatment provides improved relief from cough, cold-like, flu and flu-like symptoms.
  • a coated hard gelatin capsule composition for oral administration is prepared by combining the following ingredients:
  • Triturate active ingredients and q.s. with lactose to selected capsule size.
  • the capsules are then coated with the coolant mixture as described above in Example I.
  • Administration of 1 or 2 of the above capsules to a human in need of treatment provides improved relief from cough, cold-like, flu and flu-like symptoms.
  • a soft gelatin capsule for oral administration is prepared by combining the following ingredients:
  • the fill ingredients are combined in a suitable vessel and heated with mixing at about 65'C to form a uniform solution.
  • the soft gelatin ingredients are combined and heated to about 65"C to form a uniform mixture.
  • the resulting solution is used to prepare soft gelatin capsules containing approximately 623 mg of the fill material wherein the volatile aromat ⁇ ic is incorporated into the soft gelatin capsule shell.
  • the resulting soft gelatin capsules are suitable for oral administration.

Landscapes

  • Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

Une composition pharmaceutique, destinée à être enrobée, comprend une composition à administration par voie orale, sous forme galénique unitaire, laquelle a été enrobée avec environ 0,01 % à environ 10 % en poids de la composition d'un composé aromatique volatile sélectionné dans le groupe comprenant 3-1-menthoxy propane-1,2-diol, p-menthane-3 carboxamides N-substitués et des carboxamides acycliques ainsi que leurs mélanges.
EP94914159A 1993-04-30 1994-04-13 Compositions pharmaceutiques enrobees Ceased EP0695175A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US5670193A 1993-04-30 1993-04-30
US56701 1993-04-30
PCT/US1994/004089 WO1994025009A1 (fr) 1993-04-30 1994-04-13 Compositions pharmaceutiques enrobees

Publications (1)

Publication Number Publication Date
EP0695175A1 true EP0695175A1 (fr) 1996-02-07

Family

ID=22006081

Family Applications (1)

Application Number Title Priority Date Filing Date
EP94914159A Ceased EP0695175A1 (fr) 1993-04-30 1994-04-13 Compositions pharmaceutiques enrobees

Country Status (8)

Country Link
US (1) US5827852A (fr)
EP (1) EP0695175A1 (fr)
JP (1) JPH08509725A (fr)
CN (1) CN1122103A (fr)
CA (1) CA2161217A1 (fr)
FI (1) FI955144A (fr)
NO (1) NO954146D0 (fr)
WO (1) WO1994025009A1 (fr)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1655595A (en) * 1994-04-29 1995-11-09 Mcneil-Ppc, Inc. Solid pharmaceutical dosage form containing flavored film coating
US5698181A (en) * 1994-12-09 1997-12-16 Warner-Lambert Company Breath-freshening edible compositions comprising menthol and an N-substituted-P-menthane carboxamide and methods for preparing same
GB9517031D0 (en) * 1995-08-19 1995-10-25 Procter & Gamble Confection compositions
US5626831A (en) * 1995-12-20 1997-05-06 Van Moerkerken; Arthur Method for relief and prevention of common cold, and compositions
US6469009B1 (en) 1996-04-08 2002-10-22 Ucb, S.A. Pharmaceutical compositions for the treatment of rhinitis
WO1998001134A1 (fr) * 1996-07-10 1998-01-15 Novartis Consumer Health S.A. Combinaisons pharmaceutiques de composes antihistaminiques et de terpenoides destinees a etre administrees par voie orale
ZA976189B (en) * 1996-07-12 1999-01-11 Novartis Consumer Health Sa Oral pharmaceutical combinations
WO1998024455A1 (fr) * 1996-12-06 1998-06-11 The Procter & Gamble Company Compositions pharmaceutiques ingerables pour le traitement des troubles du tractus gastro-intestinal superieur
GB9706149D0 (en) * 1997-03-25 1997-05-14 Scherer Corp R P Comestible capsules having flavoured coatings
US6564945B1 (en) * 1997-07-14 2003-05-20 Robert E. Weinstein Medication assemblage for use in sinusitis treatment regimens
US6455080B1 (en) * 1997-12-29 2002-09-24 Wm. Wrigley Jr., Company Chewing gum containing controlled release acyclic carboxamide and method of making
US6627233B1 (en) 1997-09-18 2003-09-30 Wm. Wrigley Jr. Company Chewing gum containing physiological cooling agents
DE19814256A1 (de) * 1998-03-31 1999-10-07 Asta Medica Ag Feste, schnellzerfallende Cetirizin-Formulierungen
US6555139B2 (en) 1999-06-28 2003-04-29 Wockhardt Europe Limited Preparation of micron-size pharmaceutical particles by microfluidization
US6251426B1 (en) 1999-09-02 2001-06-26 Banner Pharmacaps, Inc. Ibuprofen-containing softgels
US6992172B1 (en) * 1999-11-12 2006-01-31 Fibrogen, Inc. Recombinant gelatins
WO2001035918A1 (fr) * 1999-11-15 2001-05-25 J. Manheimer, Inc. Compositions de flaveur et d'arome de menthe
CA2419147C (fr) * 2000-08-25 2008-10-07 Kowa Company, Ltd. Composition liquide pour le remplissage de capsules d'ibuprofene et preparation de capsules
AU2002220248A1 (en) * 2000-11-06 2002-05-15 Andrx Pharmaceuticals, Inc. Once a day antihistamine and decongestant formulation
FR2822709B1 (fr) * 2001-03-30 2007-01-19 Antialis Composition pharmaceutique anti-allergique comprenant au moins un allergene et au moins un compose antihistaminique
US20030060422A1 (en) 2001-08-31 2003-03-27 Balaji Venkataraman Tannate compositions and methods of treatment
US6887926B1 (en) 2001-11-16 2005-05-03 Oatey Co. Bonding compositions for chlorinated polymers and methods of using the same
US6863901B2 (en) 2001-11-30 2005-03-08 Collegium Pharmaceutical, Inc. Pharmaceutical composition for compressed annular tablet with molded triturate tablet for both intraoral and oral administration
US6827946B2 (en) * 2001-12-05 2004-12-07 Collegium Pharmaceutical, Inc. Compositions containing both sedative and non-sedative antihistamines
CN1652692A (zh) * 2002-04-19 2005-08-10 Wm·雷格利Jr·公司 三涂层糖果片剂产品
US20040033257A1 (en) * 2002-05-30 2004-02-19 Strides Inc. Pharmaceutical formulation in a drug delivery system and process for preparing the same
JP4320217B2 (ja) * 2002-07-10 2009-08-26 剤盛堂薬品株式会社 鼻炎用経口製剤
US8092831B2 (en) * 2002-11-08 2012-01-10 Andrx Pharmaceuticals, Llc Antihistamine and decongestant system
RU2005127783A (ru) * 2003-03-03 2006-06-27 Вм. Ригли Дж. Компани (Us) Покрытие для кондитерского изделия, обладающее быстрым высвобождением ароматизатора
US20040185093A1 (en) * 2003-03-18 2004-09-23 Szymczak Christopher E. Compositions containing sucralose
US20050152967A1 (en) * 2003-03-28 2005-07-14 Pfab, Lp Dynamic variable release
EP1699298B1 (fr) * 2003-12-30 2012-09-26 Wm. Wrigley Jr. Company Produit de confiserie enrobé
BRPI0508335B1 (pt) * 2004-02-26 2019-09-03 Wrigley W M Jun Co doces e goma de mascar contendo agentes refrescantes fisiológicos
US20060062811A1 (en) 2004-09-21 2006-03-23 Szymczak Christopher E Medicinal cooling emulsions
EP1942877A4 (fr) * 2005-11-02 2011-09-14 Teikoku Pharma Usa Inc Formulations de doses orales d'ibuprofene organoleptiquement acceptables, procedes de preparation et d'utilisation de celles-ci
EP2037916A4 (fr) * 2006-04-07 2011-09-14 Mike Nicolaou Isomeres de tritoqualine purs
SI2124556T1 (sl) 2006-10-09 2015-01-30 Charleston Laboratories, Inc. Farmacevtske sestave
EP2170317A4 (fr) * 2007-02-12 2011-03-23 Mike Nicolaou Traitement de la maladie pulmonaire obstructive chonique (mpoc), du reflux gastro-oesophagien pathologique (gerd), des allergies alimentaires et autres affections et troubles gastro-intestinaux attenues par une gestion appropriee de l'histamine au moyen d'une combinaison d'inhibiteurs d'histidine decarboxylase, de medicamen
WO2008105920A1 (fr) * 2007-02-28 2008-09-04 Collegium Pharmaceutical, Inc. Combinaison d'antihistaminiques
US20090004248A1 (en) * 2007-06-29 2009-01-01 Frank Bunick Dual portion dosage lozenge form
CN101467988B (zh) * 2007-12-27 2014-07-09 北京德众万全医药科技有限公司 一种含有氨酚伪麻的药用组合物及其制备方法
US8124126B2 (en) 2008-01-09 2012-02-28 Charleston Laboratories, Inc. Pharmaceutical compositions
US20100247586A1 (en) * 2009-03-27 2010-09-30 Andreas Hugerth Multi-Portion Intra-Oral Dosage Form With Organoleptic Properties
EP2451274B1 (fr) 2009-07-08 2017-10-04 Charleston Laboratories, Inc. Compositions pharmaceutiques
RU2014116639A (ru) * 2011-09-27 2015-11-10 Вирджиния Коммонвелт Юниверсити Избирательный метаболический подход к повышению биодоступности фенилэфрина и других фенольных биологически активных веществ при пероральном приеме
US9212290B2 (en) 2012-01-27 2015-12-15 Celanese Acetate Llc Substituted cellulose acetates and uses thereof
US9023757B2 (en) 2012-01-27 2015-05-05 Celanese Acetate Llc Substituted cellulose acetates and uses thereof
US9167830B2 (en) 2012-01-27 2015-10-27 Celanese Acetate Llc Substituted cellulose acetates and uses thereof
WO2014046681A1 (fr) 2012-09-24 2014-03-27 Celanese Acetate Llc Bois de synthèse produit avec des adhésifs d'ester de cellulose substitué et procédés correspondants
WO2014046679A1 (fr) 2012-09-24 2014-03-27 Celanese Acetate Llc Articles stratifiés en bois comprenant des adhésifs d'ester de cellulose substitué et procédés correspondants
WO2015023675A2 (fr) 2013-08-12 2015-02-19 Pharmaceutical Manufacturing Research Services, Inc. Comprimé extrudé anti-abus à libération immédiate
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US10172797B2 (en) 2013-12-17 2019-01-08 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
CA3195252A1 (fr) 2013-12-24 2015-07-02 Durect Corporation Utilisations de sulfates de cholesterol oxygenes (ocs)
AU2015290098B2 (en) 2014-07-17 2018-11-01 Pharmaceutical Manufacturing Research Services, Inc. Immediate release abuse deterrent liquid fill dosage form
WO2016064873A1 (fr) 2014-10-20 2016-04-28 Pharmaceutical Manufacturing Research Services, Inc. Forme galénique anti-abus de remplissage de liquide à libération prolongée
JP2019507181A (ja) 2016-03-04 2019-03-14 チャールストン ラボラトリーズ，インコーポレイテッド 医薬組成物
CN115607531A (zh) 2016-11-14 2023-01-17 王明武 用于治疗眼表疾病的制剂

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3515781A (en) * 1967-10-12 1970-06-02 Johnson & Johnson Cold capsule
GB1353381A (en) * 1971-02-04 1974-05-15 Wilkinson Sword Ltd Substituted p-menthanes and compositions containing them
US4136163A (en) * 1971-02-04 1979-01-23 Wilkinson Sword Limited P-menthane carboxamides having a physiological cooling effect
GB1421743A (en) * 1972-04-18 1976-01-21 Wilkinson Sword Ltd Ingestible topical and other compositions
LU68016A1 (fr) * 1973-07-13 1975-04-11
JPS5888334A (ja) * 1981-11-20 1983-05-26 Takasago Corp ３−ｌ−メントキシプロパン−１、２−ジオ−ル
JPS61194049A (ja) * 1985-02-22 1986-08-28 Takasago Corp ｌ−メンチル３−ヒドロキシブチレ−ト，その製造法およびこれを有効成分とする冷感剤
EP0310299A1 (fr) * 1987-09-28 1989-04-05 The Procter & Gamble Company Dérivés d'ester de bêta-aminoacide et de composé alcoolique actif à durée d'activité prolongée
US5098715A (en) * 1990-12-20 1992-03-24 Burroughs Wellcome Co. Flavored film-coated tablet
BR9205827A (pt) * 1991-04-04 1994-06-28 Procter & Gamble Composições farmacêuticas ingeriveis para tratamento de distúrbios do trato gastrintestinal superior

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9425009A1 *

Also Published As

Publication number Publication date
FI955144A (fi) 1995-10-31
CA2161217A1 (fr) 1994-11-10
FI955144A0 (fi) 1995-10-27
NO954146L (no) 1995-10-18
US5827852A (en) 1998-10-27
WO1994025009A1 (fr) 1994-11-10
NO954146D0 (no) 1995-10-18
JPH08509725A (ja) 1996-10-15
CN1122103A (zh) 1996-05-08

Similar Documents

Publication Publication Date Title
US5827852A (en) Coated pharmaceutical compositions
CA2146637C (fr) Compositions pharmaceutiques et methodes pour traiter les symptomes du rhume
US5484606A (en) Process for reducing the precipitation of difficulty soluble pharmaceutical actives
EP0248447B1 (fr) Formulations à libération retardée
AU706890B2 (en) Process for solubilizing difficultly soluble pharmaceutical actives
AU7604094A (en) Compositions containing an amino acid salt of propionic acid non-steroidal anti-inflammatory agent and at least one of a decongestant, an expectorant, an antihistamine and an antitussive
JPH0948728A (ja) 解熱鎮痛剤
US20240041777A1 (en) Pharmaceutical capsule containing at least two tablets
AU2002317772B2 (en) Swallow tablet comprising paracetamol
EP1014983A1 (fr) Compositions et procedes de traitement de troubles respiratoires
AU2002317772A1 (en) Swallow tablet comprising paracetamol
CA2170485C (fr) Compositions renfermant un sel d'acide propionique d'amino-acide, agents anti-inflammatoires non steroidiques utilises avec la cafeine
JP2006001920A (ja) 医薬製剤
JP2009242366A (ja) 持続性解熱鎮痛消炎剤
WO2008044331A1 (fr) Préparation solide comprenant de l'ibuprofène et de l'acide tranexamique
JPH08506808A (ja) 呼吸障害治療用組成物の製造における鎮痛剤ｓ（＋）対掌体の利用
JPH0656677A (ja) 制酸剤組成物
JPH083066A (ja) かぜ薬製剤
JP2007031281A (ja) イブプロフェン含有フィルムコーティング錠剤
JP2019019128A (ja) フィルムコーティング錠
CN1114188A (zh) 包含矫味的薄膜包衣的固体药物剂型
JP2022132186A (ja) 医薬組成物
JP2022087085A (ja) イブプロフェンを含有する固形製剤
JP2022167880A (ja) 固形製剤

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19950926

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU NL PT SE

17Q First examination report despatched

Effective date: 19960404

GRAG Despatch of communication of intention to grant

Free format text: ORIGINAL CODE: EPIDOS AGRA

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED

18R Application refused

Effective date: 19980223